DAEWON PHARMACEUTICAL CO.,LTD
Financials
Valuation Metrics
DAEWON PHARMACEUTICAL CO.,LTD's Market Cap is ₩1868B. At end of 2025 it was ₩2680B. Ranked #833 of 2,405 in KR market (top 35%), #456 of 778 on KOSPI (top 59%), #93 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 40%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 186.82B KRW | KR#833/2,405 Sec#93/231 |
| Revenue | 614.64B KRW | KR#550/2,405 Sec#23/231 |
| Net Income | 288.5M KRW | KR#1,527/2,405 Sec#106/231 |
| Total Assets | 573.33B KRW | KR#709/2,405 Sec#39/231 |
| Net Assets | 275.73B KRW | KR#759/2,405 Sec#50/231 |
| Employees | 1,332 | KR#196/2,405 Sec#11/231 |
| Value | ||
| P/E | 647.66x | KR#1,541/2,405 Sec#106/231 |
| P/B | 0.68x | KR#1,164/2,405 Sec#67/231 |
| P/S | 0.30x | KR#641/2,405 Sec#17/231 |
| FCF Yield | 6.70% | KR#790/2,405 Sec#37/231 |
| Profitability | ||
| ROE | 0.10% | KR#1,536/2,405 Sec#106/231 |
| ROA | 0.05% | KR#1,537/2,405 Sec#106/231 |
| Op. Margin | -0.02% | KR#1,600/2,405 Sec#112/231 |
| Revenue Growth | 1.83% | KR#1,395/2,405 Sec#138/231 |
| Financial Health | ||
| Debt Ratio | 107.93% | KR#1,614/2,405 Sec#185/231 |
| Total Debt | 368.87B KRW | KR#362/2,405 Sec#17/231 |
| FCF | 12.51B KRW | KR#653/2,405 Sec#38/231 |
| Cash | 23.73B KRW | KR#1,144/2,405 Sec#77/231 |
| Current Ratio | 1.12x | KR#1,572/2,405 Sec#160/231 |
| Dividend | ||
| Div. Yield | 2.88% | KR#692/2,405 Sec#34/231 |
| Div. Growth | -16.67% | KR—/2,405 Sec—/231 |
| Performance | ||
| 1Y Return | -35.97% | KR#1,623/2,405 Sec#132/231 |
| 1M Return | 5.58% | KR#158/2,405 Sec#14/231 |
| From 52W High | -39.06% | KR#718/2,405 Sec#50/231 |
| 1Y MDD | -46.17% | KR#789/2,405 Sec#59/231 |
| Trading | ||
| Volume | 408,148 shares | KR#194/2,405 Sec#11/231 |
| Trading Value | 3.44B KRW | KR#346/2,405 Sec#31/231 |
| Foreign Own. | 13.12% | KR#370/2,405 Sec#26/231 |
| Per Share | ||
| EPS | 13 KRW | KR#1,539/2,405 Sec#106/231 |
| BPS | 12,294 KRW | KR#837/2,405 Sec#58/231 |
Company Info
Daewon Pharmaceutical, incorporated in 1961, currently holds 11 subsidiaries, with Beijing Skinlala's liquidation expected by 2025. The company's core business involves manufacturing and selling pharmaceuticals, cosmetics, and health functional foods, supplying new drugs, incrementally modified drugs, and generic drugs to domestic medical institutions. Leveraging excellent GMP-certified production facilities and specialized products, Daewon Pharmaceutical engages in CMO business, exports finished pharmaceuticals and medical devices, and operates a health functional food business focused on Jangdaewon. The company is headquartered in Seongdong-gu, Seoul.